Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO) announced that it has opened a new office in Argentina.
Oscar Podesta, Chiltern Executive Director, Latin America, leads this endeavor.“Our office, strategically located in suburban Pilar, is a natural next step to our development in Argentina. The office’s state-of-the-art facilities and technology are designed to support our growing client needs in Mexico, Chile, Peru and throughout all Latin America, complementing Chiltern’s Sao Paulo, Brazil office,” commented Oscar.
“Chiltern’s opening of the Buenos Aires office in 2010 continues our globalization effort following the opening of four new offices in 2009,” stated Glenn Kerkhof, Chiltern CEO. “Chiltern’s strong presence in Argentina, Brazil, Mexico and the entire Latin American region demonstrates our commitment to providing high quality services globally.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.